Equipoise is not an ideal steroid for the drug tested athlete however. This drug has the tendency to produce detectable metabolites in the urine months after use, a worry most commonly associated with Deca-Durabolin. This is of course due to the high oil solubility of long chain esterified injectable steroids, a property which enables the drug to remain deposited in fatty tissues for extended periods of time. While this will reliably slow the release of steroid into the blood stream, it also allows small residual amounts to remain present in the body far after the initial injection. The release of stubborn stores of hormone would no doubt also be enhanced around contest time, a period when the athlete drastically attempts to mobilize unwanted body fat. If enough were used in the off-season, the athlete may actually fail a drug screen for boldenone although many months may have past since the drug was last injected.
Testosterone and its derivate are made synthetically pharmaceutically as drugs for many different treatments. Pharmaceutical research of anabolic steroid is not focused a lot on muscle grow in healthy individuals but only in some aging related diseases like sarcopenia – the loss of skeletal muscle mass and strength as a result of aging. Osteoporosis is one of the aging diseases that is also sometimes treated with anabolic steroids. In all these treatments, serious hormonal misbalance is highly possible, and a reaction of other, not targeted tissues. Some of the side effects using anabolic steroids can lead to liver conditions like peliosis hepatis – blood-filled cysts replacing healthy liver cells. This condition is often diagnosed late when it is already life threatening to treat liver failure present or intra-abdominal bleeding start.
However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.